Partial
Not Aligned
Patient Risk:
Moderate
Summary
Several core label-consistent facts are present (indication, prescription use, vaginal insert nature, and contraindication concept via estrogen-sensitive breast cancer caution and pregnancy/lactation risk summary). However, multiple dosing/administration details and multiple safety/population statements are not supported or conflict with the provided label excerpts (e.g., dosing frequency of 2–3x/week, insertion time of 2 minutes, and drug identity/ingredient mismatch with the provided INTRAROSA label text). Additional statements about mechanism effects are either not supported by the provided label excerpt or are overstated.
Category Scores
Accurate Statements
Intrarosa is a vaginal insert containing ospemifene.
The provided INTRAROSA label excerpts describe INTRAROSA as a “vaginal insert: 6.5 mg of prasterone”. No statement in the provided label excerpts supports ospemifene as the ingredient.
Intrarosa is available by prescription only.
No label excerpt provided explicitly states “prescription only.”
Intrarosa is a steroid indicated for the treatment of moderate to severe dyspareunia due to menopause (vulvar and vaginal atrophy).
Label 1 INDICATIONS AND USAGE: “INTRAROSA is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.”
Ospemifene has undergone clinical trials to evaluate its safety and efficacy for treating painful sex in postmenopausal women.
Label 14 CLINICAL STUDIES: effectiveness examined in two 12-week placebo-controlled efficacy trials in postmenopausal women with moderate to severe dyspareunia.
Unsupported Statements
Intrarosa is a prescription medication used to treat moderate to severe pain associated with dyspareunia (painful sex) in postmenopausal women.
Indication partially supported, but the label excerpt does not explicitly state “prescription medication” nor use the phrasing “postmenopausal women” in the indication section excerpt (it states due to menopause; clinical studies excerpts include postmenopausal women).
Intrarosa is a vaginal insert containing ospemifene.
Provided label excerpts specify the insert contains 6.5 mg of prasterone, not ospemifene (no support for ospemifene in the provided excerpts).
Ospemifene is a selective estrogen receptor modulator (SERM).
The provided label excerpts do not describe ospemifene as a SERM. The label excerpt provided discusses prasterone mechanism (converted into androgens/estrogens) and does not describe ospemifene as a SERM.
Ospemifene helps to restore vaginal tissue elasticity and thickness.
The provided label excerpts do not mention restoring vaginal tissue elasticity/thickness.
Intrarosa should be inserted into the vagina 2-3 times a week.
Provided label excerpt states: “Administer one INTRAROSA vaginal insert once daily at bedtime.” No support for 2–3 times per week.
Intrarosa is inserted into the vagina for 2 minutes.
Provided label excerpt does not specify any insertion dwell time (it specifies once daily at bedtime using the provided applicator).
The vaginal insert releases the medication locally.
No statement in the provided label excerpts describes local release of medication.
Intrarosa helps to increase estrogen levels in the vagina.
Label excerpt 12.1 states prasterone is converted into active androgens and/or estrogens; it does not specifically claim “increase estrogen levels in the vagina.”
Intrarosa alleviates painful sex.
The label excerpt supports treatment of dyspareunia severity; it does not use the phrase “painful sex” in the indication excerpt. (This is close to dyspareunia but not explicitly stated as such in the provided label excerpt.)
Ospemifene has beneficial effects on vaginal dryness and itching.
The provided label excerpt only discusses dyspareunia and vulvar/vaginal atrophy symptoms; it does not mention vaginal dryness/itching outcomes.
Intrarosa may cause side effects including vaginal bleeding.
The provided label excerpt includes contraindication related to undiagnosed abnormal genital bleeding, but does not provide adverse reaction statements listing vaginal bleeding.
Intrarosa may cause side effects including genital discomfort.
No adverse reactions list excerpt was provided that mentions genital discomfort.
Intrarosa may cause side effects including allergic reactions.
No adverse reactions excerpt provided that mentions allergic reactions.
Intrarosa is not recommended for women with estrogen-sensitive cancer.
The provided label excerpt states estrogen is a metabolite of prasterone and “Use of exogenous estrogen is contraindicated in women with a known or suspected history of breast cancer” and “INTRAROSA has not been studied in women with a history of breast cancer.” It does not use the phrase “estrogen-sensitive cancer” or “not recommended”; however it partially aligns with breast cancer history contraindication concept.
Intrarosa is not recommended for women who are pregnant.
Label excerpt 8.1 pregnancy states INTRAROSA is indicated only in postmenopausal women and states no data; it does not explicitly say “not recommended.”
Intrarosa is not recommended for women who are breastfeeding.
Label excerpt 8.2 lactation states indicated only in postmenopausal women and no information; it does not explicitly say “not recommended.”
Intrarosa is a patented medication.
No patent/exclusivity or “patented medication” statement is present in the provided label excerpts.
Intrarosa exclusivity is protected until 2026.
No exclusivity/patent horizon statement exists in the provided label excerpts.
Approved biosimilars may enter the market sooner, depending on regulatory approvals and the manufacturer's decision to grant licensing agreements.
No statements about biosimilars, regulatory timing, or licensing agreements exist in the provided label excerpts.
Contradictions
High
AI Statement
Intrarosa is a vaginal insert containing ospemifene.
Label Reference
Label 3 DOSAGE FORMS AND STRENGTHS: “Vaginal insert: 6.5 mg of prasterone…”
High
AI Statement
Intrarosa should be inserted into the vagina 2-3 times a week.
Label Reference
Label 2 DOSAGE AND ADMINISTRATION: “Administer one INTRAROSA vaginal insert once daily at bedtime”
Medium
AI Statement
Intrarosa is inserted into the vagina for 2 minutes.
Label Reference
Provided label excerpt 2 does not specify a 2-minute insertion duration; the label only specifies once daily at bedtime using the provided applicator.
Important Omissions
Contraindication requires evaluation for undiagnosed abnormal genital bleeding prior to consideration of INTRAROSA treatment.
Importance:
Moderate
Label-supported contraindication context: estrogen is a metabolite of prasterone; use of exogenous estrogen contraindicated in women with known or suspected history of breast cancer; INTRAROSA not studied in women with history of breast cancer.
Importance:
Moderate
Specific administration instructions: “using the provided applicator” and “once daily at bedtime” (the audited response gives incorrect frequency and adds an unsupported 2-minute duration).
Importance:
High
Mechanism of action statement in provided label excerpt: prasterone is an inactive endogenous steroid converted into active androgens and/or estrogens; mechanism of action not fully established.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Incorrect ingredient (ospemifene vs prasterone) and incorrect administration frequency (2–3x/week vs once daily) could meaningfully mislead treatment use. Additional unsupported statements about dwell time further increase misuse risk relative to the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Major inconsistencies with label: ingredient mismatch (ospemifene vs prasterone) and administration schedule mismatch (2–3 times/week and 2-minute insertion vs once daily at bedtime).
Suggested Improvement
Use label-supported content: INTRAROSA contains 6.5 mg prasterone; administer one vaginal insert once daily at bedtime using the provided applicator; avoid adding unsupported insertion duration and unsupported ingredient/mechanism statements not present in the provided label excerpts.